静脉输入的前列腺素E1 (阿尔普拉斯塔迪尔) 玻尿酸在动脉导管依赖性心脏病中:有效或绝对禁忌?
Jose L Colín Ortiz1, Angel Cruz Hernández1, Jorge A Silva Estrada1
1Department of Paediatric Cardiology, National Institute of Paediatrics, Coyoacan, Mexico City, Mexico.
Cardiology in the young
|July 5, 2023
概括
在三名肺动脉缩患者中,阿尔普拉斯塔迪尔胆囊剂有效逆转了导管,使其稳定,以便进行心脏导管. 这种干预改善了肺血流,使得成功的手术没有并发症.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 新生儿重症监护中心新生儿重症监护中心
- 药理学 药理学是指药理学的学科.
背景情况:
- 普拉斯塔格兰丁E1 (阿尔普拉斯塔迪尔) 用于血管通道依赖的先天性心脏病 (CHD) 和肺高血压.
- 已经建立了阿尔普拉斯塔迪尔的静脉输液方案,涉及加载剂和维护剂的延迟开始作用.
研究的目的:
- 报告在心脏导管治疗期间经历管道的肺动脉缩患者中服用阿尔普拉斯塔迪尔的疗效.
- 评估阿尔普拉斯塔迪尔 (alprostadil bolus) 对肺血流和患者稳定性的直接影响.
主要方法:
- 三名患有肺动脉缩的患者的病例系列,在心脏导管治疗过程中由于导管而出现超性发作.
- 服用阿尔普拉斯塔迪尔玻尿酸剂量来逆转导管.
- 随后,在肺动脉中成功安装了支架.
主要成果:
- 在这三名患者中,阿尔普拉斯塔迪尔胆量注射立即逆转了导管.
- 肺部血液流量增加,导致患者的病情立即稳定.
- 在没有严重并发症或囊后的后续症状的情况下,成功安装了支架.
结论:
- 在心脏导管治疗期间,阿尔普拉斯塔迪尔玻尿酸可以作为肺动脉缩患者肺动脉缩的有效紧急治疗方法.
- 需要进行进一步的研究,以确定阿尔普拉斯塔迪尔作为危及生命的导管的推干预措施.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
218
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
218
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
507
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
507
Drug Delivery: Enteral Route
518
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
518
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
566
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
566


